These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2134510)

  • 1. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.
    D'Argenio DZ
    Math Biosci; 1990 Apr; 99(1):105-18. PubMed ID: 2134510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A program package for simulation and parameter estimation in pharmacokinetic systems.
    D'Argenio DZ; Schumitzky A
    Comput Programs Biomed; 1979 Mar; 9(2):115-34. PubMed ID: 761456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.
    Merlé Y; Mentré F
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):101-25. PubMed ID: 8576840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies.
    Duffull SB; Graham G; Mengersen K; Eccleston J
    J Biopharm Stat; 2012; 22(1):16-29. PubMed ID: 22204524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.
    Daimon T; Goto M
    Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Bayesian estimation of pharmacokinetic parameters.
    Tsuchiwata S; Mihara K; Yafune A; Ogata H
    Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling.
    Dosne AG; Bergstrand M; Harling K; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):583-596. PubMed ID: 27730482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design and analysis of parallel experiments to produce structurally identifiable models.
    Cheung SY; Yates JW; Aarons L
    J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):93-100. PubMed ID: 23300030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic parameter estimation by numerical algorithms and multiple linear regression: application to pharmacokinetics.
    Yeh KC; Kwan KC
    J Pharm Sci; 1979 Sep; 68(9):1120-4. PubMed ID: 501533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of new measures of nonlinearity to parameter estimation and simulations in individual pharmacokinetic analyses.
    Khinkis L; Crotzer M
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):43-52. PubMed ID: 30607795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation for clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance.
    Ishida K; Kayano Y; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2007 Nov; 30(11):2159-62. PubMed ID: 17978492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.
    Kelman AW; Whiting B; Bryson SM
    Br J Clin Pharmacol; 1982 Aug; 14(2):247-56. PubMed ID: 7104175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic methods for achieving and maintaining stationary plasma levels in the venous administration of drugs].
    Iamboliev I; Genov D
    Khirurgiia (Sofiia); 1990; 43(5):46-53. PubMed ID: 2102938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear pharmacokinetic models and vanishing exponential terms: implications in pharmacokinetics.
    Wagner JG
    J Pharmacokinet Biopharm; 1976 Oct; 4(5):395-425. PubMed ID: 1003327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.